» Articles » PMID: 25218797

Heterelogous Expression of Mutated HLA-G Decreases Immunogenicity of Human Embryonic Stem Cells and Their Epidermal Derivatives

Overview
Journal Stem Cell Res
Publisher Elsevier
Specialty Cell Biology
Date 2014 Sep 15
PMID 25218797
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Human embryonic stem cells (hESCs) are capable of extensive self-renewal and expansion and can differentiate into any somatic tissue, making them useful for regenerative medicine applications. Allogeneic transplantation of hESC-derived tissues from results in immunological rejection absent adjunctive immunosuppression. The goal of our study was to generate a universal pluripotent stem cell source by nucleofecting a mutated human leukocyte antigen G (mHLA-G) gene into hESCs using the PiggyBac transposon. We successfully generated stable mHLA-G(EF1α)-hESC lines using chEF1α promoter system that stably expressed mHLA-G protein during prolonged undifferentiated proliferation andin differentiated embryoid bodies as well as teratomas. Morphology, karyotype, and telomerase activity of mHLA-G expressing hESC were normal. Immunofluorescence staining and flow cytometry analysis revealed persistent expression of pluripotent markers, OCT-3/4 and SSEA-4, in undifferentiated mHLA-G(EF1α)-hESC. Nucleofected hESC formed teratomas and when directed to differentiate into epidermal precursors, expressed high levels of mHLA-G and keratinocyte markers K14 and CD29. Natural killer cell cytotoxicity assays demonstrated a significant decrease in lysis of mHLA-G(EF1a)-hESC targets relative to control cells. Similar results were obtained with mHLA-G(EF1α)-hESC-derived epidermal progenitors (hEEP). One way mixed T lymphocyte reactions unveiled that mHLA-G(EF1a)-hESC and -hEEP restrained the proliferative activity of mixed T lymphocytes. We conclude that heterologous expression of mHLA-G decreases immunogenicity of hESCs and their epidermal differentiated derivatives.

Citing Articles

Human pluripotent stem cell-derived hepatic progenitors exhibit a partially hypoimmunogenic phenotype and actively inhibit immune responses.

Gantier M, Menoret S, Fourrier A, Delbos F, Nguyen T, Anegon I Front Immunol. 2025; 16:1507317.

PMID: 40070824 PMC: 11893836. DOI: 10.3389/fimmu.2025.1507317.


Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy.

Fang M, Allen A, Luo C, Finn J Front Immunol. 2024; 15:1457629.

PMID: 39281684 PMC: 11392856. DOI: 10.3389/fimmu.2024.1457629.


Cell-drug conjugates.

Wang Y, Shi J, Xin M, Kahkoska A, Wang J, Gu Z Nat Biomed Eng. 2024; 8(11):1347-1365.

PMID: 38951139 PMC: 11646559. DOI: 10.1038/s41551-024-01230-6.


Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation.

Netsrithong R, Garcia-Perez L, Themeli M Front Immunol. 2024; 14:1325209.

PMID: 38283344 PMC: 10811463. DOI: 10.3389/fimmu.2023.1325209.


Hypoimmune cells resist rejection in monkeys.

Borrero Borrego A, Gill S Nat Biotechnol. 2023; 42(3):380-382.

PMID: 37872412 DOI: 10.1038/s41587-023-02013-1.